Key Takeaways
- • Apollo Global Management is in advanced discussions to acquire Johnson & Johnson's DePuy Synthes orthopedics unit in a transaction valued at approximately $20 billion, according to Bloomberg sources familiar with the matter.
- • DePuy Synthes, J&J's orthopedics division, has attracted interest from multiple private equity firms, but Apollo's alternative asset management platform positions it as a leading contender for the separation.
- • The potential acquisition represents a significant strategic move for Apollo to expand its portfolio into healthcare-focused asset classes and diversify its alternative investment offerings.
- • J&J has been actively pursuing divestiture of the orthopedics unit as part of its broader portfolio realignment strategy.
Summary
Apollo Global Management Inc., the alternative asset manager, is in active negotiations to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, according to people familiar with the confidential discussions. The transaction is being valued at close to $20 billion, marking a substantial deal in the healthcare services and medical devices sector.
DePuy Synthes operates as J&J's orthopedics division and has been identified as a non-core asset the conglomerate has been seeking to divest. The unit's separation process has generated significant interest among multiple private equity firms competing for the acquisition. Apollo's involvement signals confidence from the alternative asset management community in the unit's standalone economics and long-term value creation potential.
The discussions remain in preliminary stages, with sources requesting anonymity given the private nature of negotiations. The valuation at approximately $20 billion reflects market expectations for a mature, globally diversified orthopedics platform with established market position, manufacturing infrastructure, and customer relationships. For Apollo Global Management, the potential acquisition would represent a substantial healthcare-sector deployment and an extension of the firm's private equity capabilities into the medical technology space.
J&J's decision to separate DePuy Synthes aligns with broader strategic initiatives by large pharmaceutical conglomerates to streamline operations and focus capital on core pharmaceutical and consumer health segments. The competing interest from multiple private equity acquirers suggests robust market demand for established healthcare assets with recurring revenue streams and stable cash generation characteristics.
DePuy Synthes operates as J&J's orthopedics division and has been identified as a non-core asset the conglomerate has been seeking to divest. The unit's separation process has generated significant interest among multiple private equity firms competing for the acquisition. Apollo's involvement signals confidence from the alternative asset management community in the unit's standalone economics and long-term value creation potential.
The discussions remain in preliminary stages, with sources requesting anonymity given the private nature of negotiations. The valuation at approximately $20 billion reflects market expectations for a mature, globally diversified orthopedics platform with established market position, manufacturing infrastructure, and customer relationships. For Apollo Global Management, the potential acquisition would represent a substantial healthcare-sector deployment and an extension of the firm's private equity capabilities into the medical technology space.
J&J's decision to separate DePuy Synthes aligns with broader strategic initiatives by large pharmaceutical conglomerates to streamline operations and focus capital on core pharmaceutical and consumer health segments. The competing interest from multiple private equity acquirers suggests robust market demand for established healthcare assets with recurring revenue streams and stable cash generation characteristics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.